Your browser doesn't support javascript.
Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD.
Carr, Edward J; Kronbichler, Andreas; Graham-Brown, Matthew; Abra, Graham; Argyropoulos, Christos; Harper, Lorraine; Lerma, Edgar V; Suri, Rita S; Topf, Joel; Willicombe, Michelle; Hiremath, Swapnil.
  • Carr EJ; The Francis Crick Institute, London, UK.
  • Kronbichler A; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Graham-Brown M; Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
  • Abra G; Satellite Healthcare, San Jose, California, USA.
  • Argyropoulos C; Division of Nephrology, Department of Medicine, Stanford University, Palo Alto, California, USA.
  • Harper L; Division of Nephrology, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA.
  • Lerma EV; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Suri RS; Section of Nephrology, University of Illinois at Chicago/Advocate Christ Medical Center, Oak Lawn, Illinois, USA.
  • Topf J; Research Institute, University Health Center, Department of Medicine, McGill University, Montreal, Québec, Canada.
  • Willicombe M; Department of Medicine, Oakland University William Beaumont School of Medicine, Detroit, Michigan, USA.
  • Hiremath S; Department of Inflammation and Immunity, Imperial College, London, UK.
Kidney Int Rep ; 6(9): 2292-2304, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1404736
ABSTRACT
The effects of the coronavirus disease-2019 (COVID-19) pandemic, particularly among those with chronic kidney disease (CKD), who commonly have defects in humoral and cellular immunity, and the efficacy of vaccinations against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are uncertain. To inform public health and clinical practice, we synthesized published studies and preprints evaluating surrogate measures of immunity after SARS-CoV-2 vaccination in patients with CKD, including those receiving dialysis or with a kidney transplant. We found 35 studies (28 published, 7 preprints), with sample sizes ranging from 23 to 1140 participants and follow-up ranging from 1 week to 1 month after vaccination. Seventeen of these studies enrolled a control group. In the 22 studies of patients receiving dialysis, the development of antibodies was observed in 18% to 53% after 1 dose and in 70% to 96% after 2 doses of mRNA vaccine. In the 14 studies of transplant recipients, 3% to 59% mounted detectable humoral or cellular responses after 2 doses of mRNA vaccine. After vaccination, there were a few reported cases of relapse or de novo glomerulonephritis, and acute transplant rejection, suggesting a need for ongoing surveillance. Studies are needed to better evaluate the effectiveness of SARS-CoV-2 vaccination in these populations. Rigorous surveillance is necessary for detection of long-term adverse effects in patients with autoimmune disease and transplant recipients. For transplant recipients and those with suboptimal immune responses, alternate vaccination platforms and strategies should be considered. As additional data arise, the NephJC COVID-19 page will continue to be updated (http//www.nephjc.com/news/covid-vaccine).
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Language: English Journal: Kidney Int Rep Year: 2021 Document Type: Article Affiliation country: J.ekir.2021.06.027

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Language: English Journal: Kidney Int Rep Year: 2021 Document Type: Article Affiliation country: J.ekir.2021.06.027